Just like a yo-yo: House spins debt ceiling to mid-May
This article was originally published in Scrip
If not now, Americans will soon be in some need of a sturdy neck brace – if not some serious physical therapy and antianxiety drugs – after the whiplashing from Congress' latest bungee jumping with the nation's debt limit, and more dizzying entanglements ahead on spending cuts and the impending $1 trillion sequestration, with all of those affecting the biopharma industry in one way or another.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.